Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (341)	9/2/2007 4:05:30 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

This year at the DR summit: Thomas Barnes, Ph.D., Senior Vice President of Discovery, Gene Logic Inc. Reduced hurdles in lead identification are resulting in the screening of druggable targets with weaker disease hypotheses, increasing the risk and thus incidence of programs that fail in the intended therapeutic area due to lack of efficacy. Nevertheless, the high-quality chemical matter that results can be used to probe target function and thereby link the corresponding compounds to new therapeutic utility. What is required is sufficiently high throughput methodologies to make de novo links between specific compounds and disease. We have integrated a set of technologies that provide the means of efficiently associating compounds with potential new therapeutic utility. This is in contrast to the unsystematic observations classically relied upon to reveal alternative or new drug indications. The promise of these technologies is to expeditiously reduce pipeline gaps within a pharmaceutical industry whose growth is threatened by reduced (and increasingly costly) new product flow. healthtech.com Last year at the Drug Repositioning summit: The Use of Integrative Pharmacology in Drug Repositioning Louis A. Tartaglia, Ph.D., Senior Vice President and General Manager, Drug Repositioning & Selection, Gene Logic Inc. A set of technologies has been integrated to provide the means of efficiently associating compounds with potential new therapeutic utilities. These technologies could be applied to chemical entities throughout the drug discovery and development process. This would be in stark contrast to the unsystematic and serendipitous observations that are classically relied upon to reveal alternative or new drug indications. The specific technologies to be used and early proof of concept experiments are outlined and discussed. This application of reverse-chemical genetics (i.e., Target -> Compound -> Disease -> Drug) in mammalian systems will more rapidly assign disease utility to the rapidly growing orphan chemical matter within the industry. These technologies will therefore reduce pipeline gaps within the pharmaceutical industry during this critical period when growth may become threatened by reduced (and increasingly costly) new product flow.